泰山财经记者 林俊洁 实习生 王诗绮近日,步长制药(603858.SH)发布公告称,因参股公司旗下美股上市主体石榴云医股价大幅下挫,公司预计2025年确认公允价值变动损益-2.93亿元,这一金额将直接减少同年归母净利润,但由于该损益属于非经常性损益可予以扣除,不会影响2025年度扣非后净利润。作为七乐康数字医疗实质控股的美股上市公司,石榴云医(POM)于2025年10月8日(美国纽约时间)在...
Source Link泰山财经记者 林俊洁 实习生 王诗绮近日,步长制药(603858.SH)发布公告称,因参股公司旗下美股上市主体石榴云医股价大幅下挫,公司预计2025年确认公允价值变动损益-2.93亿元,这一金额将直接减少同年归母净利润,但由于该损益属于非经常性损益可予以扣除,不会影响2025年度扣非后净利润。作为七乐康数字医疗实质控股的美股上市公司,石榴云医(POM)于2025年10月8日(美国纽约时间)在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.